Actemra litigation
Claims allege that Actemra, a rheumatoid arthritis infusion, was associated with cardiovascular and lung injuries that never appeared on its warning label.
Free case review
What the claims allege
Actemra (tocilizumab) entered the market without the cardiovascular warnings carried by competing rheumatoid arthritis drugs, and adverse event reporting later associated it with heart attack, stroke, lung disease, and pancreatitis. Claims allege patients and physicians were deprived of the information needed to weigh those risks.
Injuries named in the litigation
- Heart attack and heart failure
- Stroke
- Interstitial lung disease
- Pancreatitis
- Gastrointestinal perforation
Who may qualify
If you received Actemra infusions and suffered a heart attack, stroke, serious lung disease, or pancreatitis during or after treatment, you may have a claim. The review is free and confidential, and we will give you an honest answer either way. You pay attorney's fees only if we recover for you.
Call (888) 391‑1315 or use the form for a free, confidential review. You pay attorney's fees only if we recover for you.